vogenxinc

RALEIGH, NC, APRIL 15, 2025 — Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it will present phase 2 clinical data from Study VGX-001-012 (NCT05721729) at the Endocrine Society (ENDO) 2025 Annual Conference highlighting Mizagliflozin’s effect on hypoglycemic events and relevant pharmacodynamic indicators […]

DURHAM, NC, June 26, 2024 — Vogenx, a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced positive results from study VGX 001-012 evaluating Mizagliflozin in patients diagnosed with post-bariatric hypoglycemia (PBH).  Mizagliflozin is an investigational first-in-class, oral, small molecule drug candidate that reduces postprandial glucose absorption and secretion

Durham, N.C., April 2, 2024 – Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced that it has completed dosing of the last patient in its Phase 2 clinical study VGX-001-012 evaluating Mizagliflozin in patients diagnosed with post-bariatric hypoglycemia (PBH). Mizagliflozin is an investigational first-in-class,

DURHAM, N.C., February 15, 2024 – Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced completion of patient enrollment of a mid-Phase 2 clinical dose ranging study (VGX-001-012) evaluating Mizagliflozin in patients diagnosed with post-bariatric hypoglycemia (PBH). “Completing enrollment of this study is a significant

DURHAM, N.C., August 1, 2023 – Vogenx, a clinical-stage developer of novel therapeutics for the treatment of rare and metabolic disease, announced today the initiation of a Phase 2 clinical study of mizagliflozin for the treatment of post-bariatric hypoglycemia (PBH). PBH is a debilitating complication of bariatric surgery leading to recurrent postprandial hypoglycemia with neuroglycopenia.

DURHAM, N.C., February 1, 2022: Vogenx, Inc., a clinical-stage developer of novel therapeutics for the treatment of serious metabolic and gastrointestinal diseases, today announced the closing of an $11 million Series A financing. Proceeds from the Series A preferred stock issuance will be used to advance the Company’s therapeutic product candidate, mizagliflozin, into phase 2